Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
34 hedge funds and large institutions have $5.57M invested in Argos Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 16 closing their positions.
7,680% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $25K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less funds holding
Funds holding: 43 → 34 (-9)
26% less capital invested
Capital invested by funds: $7.55M → $5.57M (-$1.99M)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$82.3K |
| 2 |
Goldman Sachs
New York
|
+$46.9K |
| 3 |
ECM
Element Capital Management
New York
|
+$35.3K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$19.6K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$336K |
| 2 |
Renaissance Technologies
New York
|
-$99K |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$85K |
| 4 |
State Street
Boston,
Massachusetts
|
-$73.4K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$57K |
ARGS Hedge Fund Activity: Q2 2017 in Review
34 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q2 2017, worth a combined $5.57M — down 26% from $7.55M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ARGS and 7 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $82.3K. The largest seller was BlackRock, cutting an estimated $336K.
- 34 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q2 2017, down from 43 in Q1 2017.
- Funds reported $5.57M of Argos Therapeutics, Inc. stock for Q2 2017, down 26% quarter-over-quarter.
- 7 funds opened new Argos Therapeutics, Inc. positions in Q2 2017 and 16 closed out, a net change of -9 holders.
- The largest Argos Therapeutics, Inc. buyer in Q2 2017 was Millennium Management, an estimated $82.3K added.
- The largest Argos Therapeutics, Inc. seller in Q2 2017 was BlackRock, an estimated $336K sold.
Based on aggregated 13F filings for Q2 2017.